Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  Vernalis plc    VER   GB00B3Y5L754

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo Vernalis plc
Researches and develops pharmaceutical products

Vernalis Plc engages in the research, development, and commercialization of pharmaceutical products under the Tuzistra XR brand.

The company was founded by Keith G. McCullagh in 1986 and is headquartered in Winnersh, United Kingdom.

Number of employees : 103 persons.
Sales per Businesses
20152016Delta
GBP (in Million)%GBP (in Million)%
Pharmaceuticals13.25100%---
Research & Development--8.0466.8%-
Commercial--3.9933.2%-
Sales per Regions
20152016Delta
GBP (in Million)%GBP (in Million)%
Rest of Europe10.2577.4%8.1367.6% -20.67%
Rest of the World2.3217.5%2.7322.7% +18.01%
North America0.6695%1.169.7% +73.6%
United Kingdom0.0160.1%0.0050% -68.75%
Managers
NameAgeSinceTitle
Ian Garland51-Chief Executive Officer & Executive Director
Sandford Sommer-2016President & Chief Operating Officer
Peter John Fellner, PhD742003Non-Executive Chairman
David MacKney49-Chief Financial Officer & Executive Director
Pascal Borderies, MD-2014Senior Vice President-Medical Affairs
Carol C. Ferguson702003Senior Independent Non-Executive Director
Nigel Sheail512011Independent Non-Executive Director
Ian David Gilham, PhD572015Independent Non-Executive Director
Lisa Amster Schoenberg, MBA502015Non-Executive Director
Kevin Kissane612010Secretary & General Counsel
Equities
Vote QuantityFloatCompany-owned sharesTotal Float
Share A 1 526,445,230 519,607,256 98.7% 0 0.0% 98.7%
Shareholders
NameEquities%
Invesco Asset Management Ltd. 194,441,770 36.9%
Woodford Investment Management Ltd. 157,226,138 29.9%
GAM London Ltd. 47,861,787 9.09%
Legal & General Investment Management Ltd. 30,642,580 5.82%
Aviva Investors Global Services Ltd. 26,309,928 5.00%
Majedie Asset Management Ltd. 6,041,798 1.15%
Medical Strategy GmbH 5,516,929 1.05%
TD Direct Investing (Europe) Ltd. 4,859,000 0.92%
Hargreaves Lansdown Asset Management Ltd. 4,147,000 0.79%
River & Mercantile Asset Management LLP 3,516,906 0.67%
Sector Biotechnology & Medical Research - NEC
1st jan.Capitalization (M$)
VERNALIS PLC-54.41%105
INCYTE CORPORATION20.56%24 868
QUINTILES IMS HOLDINGS INC22.39%20 154
LONZA GROUP40.29%17 775
CELLTRION, INC.--.--%11 952
ALKERMES PLC-8.82%7 787
ALNYLAM PHARMACEUTICALS, INC.117.47%7 768
QIAGEN NV8.32%7 276
SEATTLE GENETICS, INC.-12.45%6 608
IONIS PHARMACEUTICALS INC-2.82%5 780
ICON PLC39.61%5 691
UNITED THERAPEUTICS CORPORATION-9.50%5 639
CHARLES RIVER LABORATORIES INTL. INC32.84%4 817
PRA HEALTH SCIENCES INC36.27%4 706
EXACT SCIENCES CORPORATION189.60%4 608
PAREXEL INTERNATIONAL CORPORATION33.40%4 450
GALAPAGOS21.53%4 445
BIO-TECHNE CORP15.23%4 424
ACADIA PHARMACEUTICALS INC.7.28%3 787
BB BIOTECH AG6.90%3 358
FIBROGEN INC92.76%3 257
Company contact information
Vernalis Plc
100 Berkshire Place
Wharfedale Road
Winnersh, Berkshire RG41 5RD

Phone : +44.118.938.0000
Fax : +44.118.938.0001
Web : www.vernalis.com
© 2017 People , Fundamentals and Ownership